Sharath Hegde is the Chief Scientific Officer at Herophilus. He has over 30 years of leadership experience in drug-discovery and early clinical development. Prior to joining Herophilus, Sharath spent 2 years at Recursion Pharmaceuticals where he was Chief Scientific Officer and 19 years at Theravance Biopharma where he was Senior Vice President and Head of Research. Before Theravance, Dr. Hegde spent 9 years at Syntex Corporation, later acquired by Roche Holdings, Ltd. Dr. Hegde obtained his Ph.D. in Pharmacology from the University of Houston and obtained his B.Pharm/M.Pharm degree in Pharmacy/Pharmacology from the University of Mumbai in India. He has participated in the discovery of several new NCEs including the marketed medicines Vibativ® (telavancin), Yupelri® (revefenancin), Aloxi® (palonosteron) and others in late stage development including ampreloxetine (Phase 3 for neurogenic orthostatic hypotension) and nezulcitinib (Phase 2 for acute lung injury and severe asthma).